1. Home
  2. PPBT vs ARTL Comparison

PPBT vs ARTL Comparison

Compare PPBT & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

N/A

Current Price

$4.05

Market Cap

3.9M

Sector

Health Care

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$5.49

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPBT
ARTL
Founded
2010
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
3.5M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
PPBT
ARTL
Price
$4.05
$5.49
Analyst Decision
Strong Buy
Hold
Analyst Count
1
2
Target Price
$30.00
N/A
AVG Volume (30 Days)
8.7K
5.9M
Earning Date
05-20-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$0.88
52 Week High
$5.18
$28.60

Technical Indicators

Market Signals
Indicator
PPBT
ARTL
Relative Strength Index (RSI) 60.47 48.94
Support Level $3.63 $2.24
Resistance Level $4.39 $5.56
Average True Range (ATR) 0.30 2.14
MACD -0.09 -0.40
Stochastic Oscillator 68.53 14.42

Price Performance

Historical Comparison
PPBT
ARTL

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: